PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aptose Biosciences Inc. (APS.TO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA03835T2002
CUSIP03835T200
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapCA$8.96M
EPS (TTM)-CA$5.76
EBITDA (TTM)-CA$28.91M
Year RangeCA$0.46 - CA$4.56
Target PriceCA$31.02
Short %0.10%
Short Ratio1.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of CA$10,000 in Aptose Biosciences Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%MayJuneJulyAugustSeptemberOctober
-100.00%
11.21%
APS.TO (Aptose Biosciences Inc.)
Benchmark (^GSPC)

Returns By Period

Aptose Biosciences Inc. had a return of -85.67% year-to-date (YTD) and -87.03% in the last 12 months. Over the past 10 years, Aptose Biosciences Inc. had an annualized return of -41.73%, while the S&P 500 had an annualized return of 11.71%, indicating that Aptose Biosciences Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-85.67%20.57%
1 month-7.69%6.34%
6 months-75.38%10.39%
1 year-87.03%32.65%
5 years (annualized)-59.46%14.43%
10 years (annualized)-41.73%11.71%

Monthly Returns

The table below presents the monthly returns of APS.TO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-19.40%-11.11%-6.67%-24.55%-20.71%-23.88%-24.51%-31.17%-0.00%-85.67%
202330.77%-22.55%10.13%-25.29%-12.31%-27.25%-39.39%43.24%-30.00%0.53%-12.63%0.90%-71.37%
2022-4.62%-8.48%12.58%-11.18%-14.57%-26.36%3.16%7.14%-21.90%-23.17%42.86%-13.33%-54.91%
2021-5.55%-3.98%48.52%-8.37%-6.67%-36.34%-17.80%11.28%-26.67%-6.55%8.56%-37.99%-69.05%
202023.67%17.71%-23.36%16.83%5.32%-15.46%-20.98%8.31%8.90%-24.65%44.74%-35.52%-23.95%
20190.00%-11.15%16.45%-4.09%5.04%25.83%-2.35%-3.90%-13.75%-1.99%33.83%103.04%182.69%
201833.09%-2.70%12.78%2.96%10.29%12.36%-23.36%-4.03%-12.07%-14.63%5.94%-14.19%-6.47%
2017-30.94%20.00%-10.00%-11.85%16.81%16.55%10.49%-1.68%5.11%10.27%28.92%5.70%53.59%
201614.44%-7.77%0.53%-19.11%14.56%-9.60%3.13%-12.73%2.78%-54.05%-8.82%45.97%-49.72%
2015-8.30%-1.59%10.32%0.88%2.90%-9.86%-7.19%18.86%-17.85%29.48%-46.87%-9.77%-47.60%
20143.51%32.20%-24.36%-3.39%-21.05%8.89%-3.06%9.47%3.85%28.09%0.60%-17.72%0.44%
20136.45%-19.70%7.55%-29.82%10.00%-4.55%-4.76%-10.00%38.89%116.00%-1.85%7.55%83.87%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of APS.TO is 3, indicating that it is in the bottom 3% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of APS.TO is 33
APS.TO (Aptose Biosciences Inc.)
The Sharpe Ratio Rank of APS.TO is 22Sharpe Ratio Rank
The Sortino Ratio Rank of APS.TO is 00Sortino Ratio Rank
The Omega Ratio Rank of APS.TO is 22Omega Ratio Rank
The Calmar Ratio Rank of APS.TO is 33Calmar Ratio Rank
The Martin Ratio Rank of APS.TO is 66Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aptose Biosciences Inc. (APS.TO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


APS.TO
Sharpe ratio
The chart of Sharpe ratio for APS.TO, currently valued at -1.03, compared to the broader market-4.00-2.000.002.00-1.03
Sortino ratio
The chart of Sortino ratio for APS.TO, currently valued at -2.69, compared to the broader market-4.00-2.000.002.004.00-2.69
Omega ratio
The chart of Omega ratio for APS.TO, currently valued at 0.70, compared to the broader market0.501.001.502.000.70
Calmar ratio
The chart of Calmar ratio for APS.TO, currently valued at -0.86, compared to the broader market0.002.004.006.00-0.86
Martin ratio
The chart of Martin ratio for APS.TO, currently valued at -1.43, compared to the broader market-10.000.0010.0020.00-1.43
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.68, compared to the broader market-4.00-2.000.002.002.68
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.58, compared to the broader market-4.00-2.000.002.004.003.58
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.49, compared to the broader market0.501.001.502.001.49
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 2.36, compared to the broader market0.002.004.006.002.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 16.32, compared to the broader market-10.000.0010.0020.0016.32

Sharpe Ratio

The current Aptose Biosciences Inc. Sharpe ratio is -1.03. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Aptose Biosciences Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00MayJuneJulyAugustSeptemberOctober
-1.03
2.98
APS.TO (Aptose Biosciences Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aptose Biosciences Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%MayJuneJulyAugustSeptemberOctober
-100.00%
0
APS.TO (Aptose Biosciences Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aptose Biosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aptose Biosciences Inc. was 100.00%, occurring on Sep 9, 2024. The portfolio has not yet recovered.

The current Aptose Biosciences Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Mar 7, 20005989Sep 9, 2024
-92.74%Jun 8, 19931429Mar 17, 1999231Feb 16, 20001660
-23.46%Feb 17, 20007Feb 25, 20002Feb 29, 20009
-9.96%Mar 1, 20002Mar 2, 20001Mar 3, 20003

Volatility

Volatility Chart

The current Aptose Biosciences Inc. volatility is 13.10%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%MayJuneJulyAugustSeptemberOctober
13.10%
2.86%
APS.TO (Aptose Biosciences Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aptose Biosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Aptose Biosciences Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items